Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Enlivex Therapeutics Ltd. Approves Purchase of Up to $1 Million in Bitcoin as Part of Cash Management Strategy Quiver Quantitative, Inc. - Wed Nov 20, 5:20PM CST

Enlivex Therapeutics plans to purchase $1 million in Bitcoin to diversify its treasury reserves amid increasing demand.Quiver AI SummaryEnlivex Therapeutics Ltd., a clinical-stage company focused on macrophage...

ENLV : 0.9293 (+10.50%)
New Strong Buy Stocks for October 23rd
New Strong Buy Stocks for October 23rd Zacks Investment Research - Wed Oct 23, 7:24AM CDT

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Rent the Runway, Inc. RENT: This designer clothing rental company has seen the Zacks Consensus Estimate for its current year earnings...

ENLV : 0.9293 (+10.50%)
PTON : 9.54 (+5.30%)
GTEC : 2.21 (-0.45%)
DSGR : 38.08 (+0.82%)
RENT : 9.60 (-0.83%)
CREA Stats, U.S. Retail Sales Featured Next Week Baystreet - Fri Jun 14, 6:27PM CDT

Monday U.S. Featured Earnings Lennar Corp. (NYSE: LEN) (Q2) EPS of $3.20, compared to $2.94 ...

FLOW.TO : 0.1500 (-3.23%)
ET.TO : 12.24 (+1.32%)
ASTL.TO : 15.71 (-1.32%)
LEN : 169.17 (+0.65%)
LZB : 43.69 (+0.67%)
DDD : 3.20 (-0.62%)
KBH : 79.40 (+2.07%)
CRMT : 44.87 (+4.18%)
DLNG : 4.48 (+5.41%)
PDCO : 20.46 (+0.89%)
SCS : 13.27 (+1.76%)
KR : 59.22 (+1.09%)
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™ Globe Newswire - Wed Aug 3, 2022

Nes-Ziona, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...

ENLV : 0.9293 (+10.50%)
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers Globe Newswire - Wed Jul 6, 2022

First clinical trial of Allocetra™ in patients with cancer builds upon promising preclinical studies demonstrating its broadly applicable immunotherapeutic...

ENLV : 0.9293 (+10.50%)
Enlivex to Present at the 2022 Jefferies Healthcare Conference Globe Newswire - Tue Jun 7, 2022

Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy...

ENLV : 0.9293 (+10.50%)
Enlivex Announces Upcoming May Conference Presentations Globe Newswire - Tue May 10, 2022

Nes-Ziona, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...

ENLV : 0.9293 (+10.50%)
Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting Globe Newswire - Mon May 9, 2022

Mesothelioma is one of the deadliest solid cancers, with few treatment options, all of which have limited efficacy. Immune checkpoint inhibitors targeting...

ENLV : 0.9293 (+10.50%)
Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra Globe Newswire - Thu May 5, 2022

Nes-Ziona, Israel, May 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...

ENLV : 0.9293 (+10.50%)
Enlivex Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead of Schedule, and Provides Strategic & Business Updates Globe Newswire - Fri Apr 29, 2022

Development of frozen formulation Allocetra™, a primary cornerstone of Enlivex’s R&D efforts during the last two years, was successfully completed in...

ENLV : 0.9293 (+10.50%)

Barchart Exclusives

3 High-Yielding Dividend Kings to Boost Your Income in 2025 and Beyond Barchart - Fri Nov 22, 6:00PM CST
These three high-quality companies are currently on sale, offering elevated yields that appeal to dividend growth investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot